Effect of Ezetimibe on preventing contrast-induced nephropathy

Investigating the effect of Ezetimibe on preventing contrast-induced nephropathy after angiography

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250702066339N1

Enrollment

128

Registered

2025-07-17

Start date

2025-07-18

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast induced nephropathy. Nephropathy induced by other drugs, medicaments and biological substances

Interventions

Intervention 1: Intervention group: A group of patients who are candidates for angiography who receive the drug ezetimibe 2 hours before angiography. This group is given one ezetimibe tablet with a do

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Being a candidate for angiography Consent to participate in research Consent to undergo testing and return after discharge

Exclusion criteria

Exclusion criteria: No angiography performed Unwillingness to participate in the research Failure to return after discharge and failure to perform necessary tests

Design outcomes

Primary

Measure	Time frame
The patient's serum creatinine level. Timepoint: Before angiography and 48 to 72 hours after angiography. Method of measurement: By laboratory kits.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrshad Edalat

Islamic Azad University

Me.edalat@iau.ir+98 21 8868 4857

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026